Vol.52 No.6 June 2004

In vivo efficacy of biapenem against mouse pneumonia infection caused by MexAB-OprM overproducing Pseudomonas aeruginosa

Toshihiko Takata¹⁾, Atsuyuki Shimizu¹⁾, Muneo Hikida¹⁾, Naomasa Gotoh²⁾ and Takeshi Nishino²⁾

¹⁾Infectious Disease Reseach Laboratories, Meiji Seika Kaisha, Ltd.,
760 Morooka-cho, Kohoku-ku, Yokohama, Kanagawa, Japan
²⁾Department of Microbiology, Kyoto Pharmaceutical University

Abstract

In vivo efficacy of biapenem (BIPM) against mouse pseudomonal pneumonia infection was compared to that of imipenem/cilastatin (IPM/CS) and meropenem (MEPM). All carbapenems showed high therapeutic efficacy against sensitive P. aeruginosa. BIPM efficacy against the MexAB-OprM overproducing strain was superior to IPM/CS and MEPM. Therapeutic response of BIPM against MexAB-OprM overproducing and MexCD-OprJ producing strain was superior to MEPM and similar to IPM/CS. BIPM effectiveness was compared to IPM/CS and MEPM using a mouse model infection with different inoculum size. In 10⁵ order CFU/lung, therapeutic efficacy of BIPM, IPM/CS, and MEPM was comparable, but in 10⁶ order CFU/lung, BIPM showed higher efficacy than IPM/CS or MEPM.

Key word

biapenem, Pseudomonas aeruginosa, MexAB-OprM, pneumonia infection model

Received

April 9, 2004

Accepted

May 11, 2004

Jpn. J. Chemother. 52 (6): 304-308, 2004